Skip to Content

Atorvastatin / ezetimibe Pregnancy and Breastfeeding Warnings

Atorvastatin / ezetimibe is also known as: Liptruzet

Atorvastatin / ezetimibe Pregnancy Warnings

Serum cholesterol and triglycerides increase during normal pregnancy. Lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little or no impact on long-term outcomes of primary hypercholesterolemia. Animal studies at high human doses were not teratogenic but there was decreased pup survival at birth, neonate, weaning, and development was delayed. Rare reports of congenital anomalies have been received following intrauterine exposure to atorvastatin. There are no adequate and well-controlled studies in human pregnancy. FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

FDA pregnancy category: X Use of atorvastatin-ezetimibe is contraindicated. Women of childbearing potential should be encouraged to use adequate contraception.

See references

Atorvastatin / ezetimibe Breastfeeding Warnings

Exposure to total ezetimibe in nursing rat pups was up to half of that observed in maternal plasma.

Use of atorvastatin-ezetimibe is not recommended. Excreted into human milk: Atorvastatin: Unknown (a small amount of another drug in this class does pass into breast milk); ezetimibe: Unknown Excreted into animal milk: Yes The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Liptruzet (atorvastatin-ezetimibe)." Merck & Company Inc, Whitehouse Station, NJ.

References for breastfeeding information

  1. "Product Information. Liptruzet (atorvastatin-ezetimibe)." Merck & Company Inc, Whitehouse Station, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.